Medicinova Inc (MNOV)

$1.37 -0.01 (-0.72%)
Market Cap 69.40M
Revenue (ttm) 410,000.00
Net Income (ttm) -12.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,926.83%
Debt to Equity Ratio 0.00
Volume 12,000
Avg Vol 43,156
Day's Range N/A - N/A
Shares Out 49.22M
Stochastic %K 9%
Beta 0.63
Analysts Strong Sell
Price Target $9.00

Company Profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, an...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 373 1500
Fax: 858 404 0048
Address:
4275 Executive Square, Suite 300, La Jolla, United States
Junecare
Junecare May. 7 at 4:12 PM
$MNOV Last night, the MNOV stock jumped to $9 for a minute. Almost an hour later, it was above $5, then, seemingly out of nowhere, dropped back to $1.43/5. Once was a glitch, twice is what?
0 · Reply
Junecare
Junecare May. 7 at 4:06 PM
$MNOV hier soir l action est monté à 9 dollars d' un coup pendant 1 min Presque une heure après cette fois ci elle montre plus de 5 dollars ,puis l. Air de rien revient au cours de 1,43/5 . Une fois c un bug ,deux fois c est quoi??
0 · Reply
laaarsas
laaarsas Apr. 28 at 6:03 PM
$MNOV This is something to stay away from right?
1 · Reply
laaarsas
laaarsas Apr. 28 at 4:02 PM
$MNOV Hi is this dead as the grave?
0 · Reply
thepalace2007
thepalace2007 Apr. 6 at 4:14 PM
$MNOV $10 stock im a buyer
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 27 at 2:43 PM
$MNOV RSI: 50.75, MACD: -0.0175 Vol: 0.05, MA20: 1.42, MA50: 1.54 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DeepBlueTitan
DeepBlueTitan Mar. 21 at 1:53 PM
$MNOV Bullish sentiment often comes from consistent upward movement in stock price.
0 · Reply
DeepBlueTitan
DeepBlueTitan Mar. 21 at 1:52 PM
$MNOV
0 · Reply
DARKP00L
DARKP00L Mar. 16 at 11:36 AM
$MNOV 07:16 on Mar. 16 2026 HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10 #tradeideas
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 2:36 PM
$MNOV Current Stock Price: $1.40
0 · Reply
Latest News on MNOV
MediciNova’s peer-reviewed ibudilast study advances clinical translation

2026-04-27T23:15:15.000Z - 16 days ago

MediciNova’s peer-reviewed ibudilast study advances clinical translation

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

Apr 27, 2026, 7:00 PM EDT - 16 days ago

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

Maxim resumes MediciNova at Buy on potential value-driving data events this year

2026-03-23T12:45:43.000Z - 7 weeks ago

Maxim resumes MediciNova at Buy on potential value-driving data events this year

MediciNova resumed with a Buy at Maxim

2026-03-23T11:36:21.000Z - 7 weeks ago

MediciNova resumed with a Buy at Maxim

MediciNova to Participate at the 38th Annual ROTH Conference

Mar 16, 2026, 7:00 AM EDT - 2 months ago

MediciNova to Participate at the 38th Annual ROTH Conference

MediciNova initiated with a Buy at H.C. Wainwright

2026-03-16T10:15:52.000Z - 2 months ago

MediciNova initiated with a Buy at H.C. Wainwright

MediciNova management to meet with Maxim

2026-02-26T14:25:55.000Z - 2 months ago

MediciNova management to meet with Maxim

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

Jan 29, 2026, 6:00 PM EST - 3 months ago

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova issues letter to shareholders

2026-01-06T14:15:37.000Z - 4 months ago

MediciNova issues letter to shareholders

2026 New Year's Greetings from the CEO

Jan 6, 2026, 9:00 AM EST - 4 months ago

2026 New Year's Greetings from the CEO

MediciNova initiated with a Buy at Lucid Capital

2026-01-05T11:41:10.000Z - 4 months ago

MediciNova initiated with a Buy at Lucid Capital

MediciNova completes patient enrollment in neuropathy trial of MN-166

2025-12-18T11:10:11.000Z - 5 months ago

MediciNova completes patient enrollment in neuropathy trial of MN-166

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Dec 18, 2025, 6:00 AM EST - 5 months ago

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

Dec 8, 2025, 6:00 AM EST - 5 months ago

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

MediciNova files $300M mixed securities shelf

2025-12-05T21:30:10.000Z - 5 months ago

MediciNova files $300M mixed securities shelf

MediciNova names Dr. Christopher Breder as Clinical and Regulatory Advisor

2025-11-18T11:10:40.000Z - 6 months ago

MediciNova names Dr. Christopher Breder as Clinical and Regulatory Advisor

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

Nov 18, 2025, 6:00 AM EST - 6 months ago

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

Nov 6, 2025, 6:00 PM EST - 6 months ago

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

MediciNova completes patient enrollment in MN-001-NATG-202 trial

2025-11-04T12:41:08.000Z - 6 months ago

MediciNova completes patient enrollment in MN-001-NATG-202 trial

MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis

2025-10-31T00:55:15.000Z - 6 months ago

MediciNova compounds demonstrate novel therapeutic approach for Atherosclerosis

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

Oct 30, 2025, 7:00 PM EDT - 6 months ago

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

Oct 6, 2025, 8:00 AM EDT - 7 months ago

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

MediciNova completes patient enrollment in COMBAT-ALS Phase 2b/3 trial

2025-09-22T12:15:46.000Z - 8 months ago

MediciNova completes patient enrollment in COMBAT-ALS Phase 2b/3 trial

MediciNova provides update on SEPA, COMBAT-ALS trial enrollment

2025-09-08T13:05:11.000Z - 8 months ago

MediciNova provides update on SEPA, COMBAT-ALS trial enrollment

MediciNova Provides Shareholder Update on Key Developments

Sep 8, 2025, 9:00 AM EDT - 8 months ago

MediciNova Provides Shareholder Update on Key Developments

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:00 AM EDT - 9 months ago

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MediciNova achieves enrollment in COMBAT-ALS clinical trial

2025-08-27T03:50:11.000Z - 9 months ago

MediciNova achieves enrollment in COMBAT-ALS clinical trial

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

Aug 26, 2025, 7:00 PM EDT - 9 months ago

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

MediciNova files to sell 25M shares of common stock for holders

2025-08-22T20:25:09.000Z - 9 months ago

MediciNova files to sell 25M shares of common stock for holders

MediciNova enters $30M equity purchase agreement

2025-07-31T23:50:31.000Z - 10 months ago

MediciNova enters $30M equity purchase agreement

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

Jul 31, 2025, 7:30 PM EDT - 10 months ago

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

MediciNova provides enrollment update for two key ongoing clinical trials

2025-07-24T10:16:32.000Z - 10 months ago

MediciNova provides enrollment update for two key ongoing clinical trials

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

Jul 24, 2025, 6:00 AM EDT - 10 months ago

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

MediciNova price target lowered to $5 from $6 at B. Riley

2025-06-16T13:20:20.000Z - 11 months ago

MediciNova price target lowered to $5 from $6 at B. Riley

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

Apr 14, 2025, 7:00 PM EDT - 1 year ago

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

Apr 8, 2025, 7:00 PM EDT - 1 year ago

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

Dec 5, 2024, 6:00 PM EST - 1 year ago

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

Nov 14, 2024, 6:00 PM EST - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Nov 11, 2024, 6:00 PM EST - 1 year ago

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

Oct 23, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Sep 30, 2024, 9:00 AM EDT - 1 year ago

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

Sep 9, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

Sep 3, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Aug 29, 2024, 7:00 PM EDT - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova Chief Business Officer David H. Crean, Ph.D.

Jun 20, 2024, 6:00 AM EDT - 2 years ago

MediciNova Chief Business Officer David H. Crean, Ph.D.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

Jun 5, 2024, 6:00 AM EDT - 2 years ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Jun 3, 2024, 6:00 AM EDT - 2 years ago

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

May 28, 2024, 6:00 AM EDT - 2 years ago

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

May 20, 2024, 6:00 AM EDT - 2 years ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

May 14, 2024, 6:00 AM EDT - 2 years ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

May 7, 2024, 6:00 AM EDT - 2 years ago

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Apr 2, 2024, 7:00 PM EDT - 2 years ago

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Mar 26, 2024, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Mar 20, 2024, 7:00 PM EDT - 2 years ago

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Mar 12, 2024, 6:30 AM EDT - 2 years ago

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Jan 17, 2024, 6:00 AM EST - 2 years ago

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Dec 21, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Dec 6, 2023, 6:00 PM EST - 2 years ago

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Nov 19, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

Oct 27, 2023, 1:00 AM EDT - 2 years ago

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Oct 10, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

MediciNova Receives Gene Therapy Milestone Payment

Oct 4, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives Gene Therapy Milestone Payment

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Sep 27, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Aug 17, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

Aug 16, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

Aug 15, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

Aug 14, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

Jun 29, 2023, 6:00 AM EDT - 3 years ago

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

May 14, 2023, 7:00 PM EDT - 3 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

Junecare
Junecare May. 7 at 4:12 PM
$MNOV Last night, the MNOV stock jumped to $9 for a minute. Almost an hour later, it was above $5, then, seemingly out of nowhere, dropped back to $1.43/5. Once was a glitch, twice is what?
0 · Reply
Junecare
Junecare May. 7 at 4:06 PM
$MNOV hier soir l action est monté à 9 dollars d' un coup pendant 1 min Presque une heure après cette fois ci elle montre plus de 5 dollars ,puis l. Air de rien revient au cours de 1,43/5 . Une fois c un bug ,deux fois c est quoi??
0 · Reply
laaarsas
laaarsas Apr. 28 at 6:03 PM
$MNOV This is something to stay away from right?
1 · Reply
laaarsas
laaarsas Apr. 28 at 4:02 PM
$MNOV Hi is this dead as the grave?
0 · Reply
thepalace2007
thepalace2007 Apr. 6 at 4:14 PM
$MNOV $10 stock im a buyer
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 27 at 2:43 PM
$MNOV RSI: 50.75, MACD: -0.0175 Vol: 0.05, MA20: 1.42, MA50: 1.54 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
DeepBlueTitan
DeepBlueTitan Mar. 21 at 1:53 PM
$MNOV Bullish sentiment often comes from consistent upward movement in stock price.
0 · Reply
DeepBlueTitan
DeepBlueTitan Mar. 21 at 1:52 PM
$MNOV
0 · Reply
DARKP00L
DARKP00L Mar. 16 at 11:36 AM
$MNOV 07:16 on Mar. 16 2026 HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10 #tradeideas
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 2:36 PM
$MNOV Current Stock Price: $1.40
0 · Reply
thepalace2007
thepalace2007 Feb. 26 at 7:12 PM
$MNOV park a little cash here this could be $8+ with approval
0 · Reply
JudyBergmark348
JudyBergmark348 Feb. 21 at 6:36 AM
$MNOV MediciNova develops small-molecule therapies for neurological and inflammatory diseases. Valuation is driven by clinical trial progress. Early-stage biotech risk remains elevated.
0 · Reply
thepalace2007
thepalace2007 Feb. 19 at 5:19 PM
$MNOV earnings after hours
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 3:08 PM
$MNOV RSI: 10.00, MACD: 0.0142 Vol: 0.10, MA20: 1.68, MA50: 1.53 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Lionish
Lionish Feb. 11 at 11:53 PM
$MNOV The company’s Chief Business Officer, David Crean, is interviewed on nano cap podcast episode 045. You can listen to it on YouTube.
0 · Reply
StreetwiseReports
StreetwiseReports Feb. 2 at 6:44 PM
Biopharmaceutical Co. Looking for Breakthrough in US$987.6M ALS Treatment Market https://ow.ly/hEbB50Y7M7h Biopharmaceutical firm MediciNova Inc. ($MNOV:NASDAQ) reports that by the end of January, it has activated 12 sites in the U.S. and enrolled 100 patients in its study assessing its ALS treatment. Discover what one analyst suggests investors should watch for from the company in the upcoming year.
0 · Reply
StreetwiseReports
StreetwiseReports Feb. 2 at 6:05 PM
Biopharma Reaches 50% Enrollment in New ALS Drug Program https://ow.ly/5yoQ50Y7KJB MediciNova Inc. ($MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm.
0 · Reply
prismmarketview
prismmarketview Jan. 30 at 2:35 PM
MediciNova (NASDAQ: $MNOV) has enrolled 100 ALS patients in its SEANOBI expanded‑access program for MN‑166 (ibudilast), marking a key milestone as it advances late‑stage development of the therapy. https://prismmarketview.com/medicinova-reaches-100-patient-milestone-in-expanded-access-program-for-als-treatment/
0 · Reply
DARKP00L
DARKP00L Jan. 29 at 11:14 PM
$MNOV 18:03 on Jan. 29 2026 MediciNova Reveals That As Of The End Of January 2026, 12 Sites In The US Are Activated And 100 Patients Have Been Enrolled In The SEANOBI Study #tradeideas
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 28 at 7:06 PM
$MNOV RSI: 75.64, MACD: 0.1090 Vol: 0.19, MA20: 1.55, MA50: 1.49 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
peepthestamp
peepthestamp Jan. 24 at 1:15 AM
$MNOV
0 · Reply